Decrease in Shiga toxin expression using a minimal inhibitory concentration of rifampicin followed by bactericidal gentamicin treatment enhances survival of Escherichia coli O157:H7-infected BALB/c mice
2011

Improving Survival of Mice Infected with E. coli O157:H7 Using Rifampicin and Gentamicin

Sample size: 56 publication Evidence: moderate

Author Information

Author(s): Rahal Elias A, Kazzi Natalie, Sabra Ahmad, Abdelnoor Alexander M, Matar Ghassan M

Primary Institution: American University of Beirut

Hypothesis

Decreasing Shiga toxin expression prior to bacterial eradication may provide a safer course of therapy for E. coli O157:H7 infections.

Conclusion

Using rifampicin followed by gentamicin effectively decreases toxin expression and improves survival in mice infected with E. coli O157:H7.

Supporting Evidence

  • Rifampicin significantly decreased Shiga toxin gene expression in vitro.
  • Mice treated with rifampicin followed by gentamicin had the highest survival rates.
  • Gentamicin alone led to the death of all treated mice by day 4.

Takeaway

This study found that giving mice a medicine to lower harmful toxins before using a stronger medicine to kill the bacteria helped them survive better.

Methodology

The study evaluated the effect of rifampicin and gentamicin on Shiga toxin expression in vitro and monitored survival in infected mice.

Limitations

The study was conducted in mice, and results may not directly translate to humans.

Participant Demographics

Adult male BALB/c mice, 4-6 weeks old.

Digital Object Identifier (DOI)

10.1186/1476-0711-10-34

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication